Skip to main content

Market Overview

Kindred Biosciences Is 'Setting The Pace In Animal Health Biologics'

Share:

Ladenburg Thalmann’s Kevin DeGeeter believes Kindred Biosciences Inc (NASDAQ: KIN) has an attractive growth opportunity in biologic therapies for the treatment of companion animals.

DeGeeter initiated coverage of the company with a Buy rating and price target of $7.50.

Setting The Pace

“We view KIN as an emerging leader in development of new biologic therapies for companion animals with two potential product launches in 2017,” the analyst mentioned.

DeGeeter expects the company to see growth opportunities, driven by its potential for higher efficiency, compared to existing therapies, convenience of dosing, potential for premium pricing, compelling specialty commercial model and opportunities to monetize its platform via global partnerships.

In addition, the analyst believes “KIN is positioned to complete three important milestones before requiring additional financial resources including: 1) launch of Zimeta in mid 2017, 2) successful completion of pilot study for epoCat (feline EPO) by 1H17, and 3) potential launch of epoCat in 1H19.”

Expectations

DeGeeter estimated that Kindred Biosciences’ equine franchise, including Zimeta, had the potential to reach $36.8 million in revenues by 2020, while epoCat could achieve sales of $12.7 million in the same time frame.

The company received approval of “effectiveness technical section” for Zimeta from the FDA.

If the FDA review approval process is rapid, Kindred Biosciences expects to receive approval for the drug application in H1 2017.

“We expect KIN to compete primarily on product consistency and eventually on breadth of product offering,” DeGeeter stated.

Latest Ratings for KIN

DateFirmActionFromTo
Jan 2021Aegis CapitalMaintainsBuy
Jul 2020Cantor FitzgeraldMaintainsOverweight
Mar 2020StifelMaintainsBuy

View More Analyst Ratings for KIN
View the Latest Analyst Ratings

 

Related Articles (KIN)

View Comments and Join the Discussion!

Posted-In: Kevin DeGeeter Ladenburg ThalmannAnalyst Color Long Ideas Initiation Analyst Ratings Trading Ideas

Latest Ratings

StockFirmActionPT
GOTUCitigroupDowngrades12.0
ATERRoth CapitalMaintains25.0
FMTXSVB LeerinkMaintains54.0
TALCitigroupDowngrades
PLXSLoop CapitalMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com